Markov model and cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer.

Tamer Refaat; Mehee Choi; Germaine Gaber; Krystyna Kiel; Minesh Mehta; William Gradishar; William Small

doi:10.1097/COC.0b013e31827e4e9a

Markov model and cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer.

Tamer Refaat, Mehee Choi, Germaine Gaber, Krystyna Kiel, Minesh Mehta, William Gradishar, William Small

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	American Journal of Clinical Oncology
Volume	37
DOIs	https://doi.org/10.1097/COC.0b013e31827e4e9a
State	Published - Jan 10 2014

Disciplines

Medicine and Health Sciences
Surgery

Access to Document

10.1097/COC.0b013e31827e4e9aLicense: Unspecified

Cite this

@article{28ff84e95fb74e6fb8ecd8de846e1e55,

title = "Markov model and cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer.",

author = "Tamer Refaat and Mehee Choi and Germaine Gaber and Krystyna Kiel and Minesh Mehta and William Gradishar and William Small",

note = "PURPOSE: Metastatic breast cancer (MBC) remains an incurable disease despite advances in treatment modalities. In 2008, the FDA approved bevacizumab with paclitaxel for the initial treatment of HER2-negative MBC. The approval was then officially revoked by the FDA in November 2011. However, both the European Medicines Agency and NCCN still endorse bevacizumab for this indication.",

year = "2014",

month = jan,

day = "10",

doi = "10.1097/COC.0b013e31827e4e9a",

language = "American English",

volume = "37",

journal = "American Journal of Clinical Oncology",

}

TY - JOUR

T1 - Markov model and cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer.

AU - Refaat, Tamer

AU - Choi, Mehee

AU - Gaber, Germaine

AU - Kiel, Krystyna

AU - Mehta, Minesh

AU - Gradishar, William

AU - Small, William

N1 - PURPOSE: Metastatic breast cancer (MBC) remains an incurable disease despite advances in treatment modalities. In 2008, the FDA approved bevacizumab with paclitaxel for the initial treatment of HER2-negative MBC. The approval was then officially revoked by the FDA in November 2011. However, both the European Medicines Agency and NCCN still endorse bevacizumab for this indication.

PY - 2014/1/10

Y1 - 2014/1/10

UR - https://www.scholars.northwestern.edu/en/publications/markov-model-and-cost-effectiveness-analysis-of-bevacizumab-in-he

U2 - 10.1097/COC.0b013e31827e4e9a

DO - 10.1097/COC.0b013e31827e4e9a

M3 - Article

VL - 37

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

ER -

Markov model and cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer.

Disciplines

Access to Document

Other files and links

Cite this